HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-CXCL10 monoclonal antibody therapy protects against the diabetic retinopathy in the mouse model induced by streptozotocin.

AbstractOBJECTIVE:
To explore the effect of CXC chemokine CXCL10 in the mice with diabetic retinopathy (DR).
METHODS:
DR models were constructed on mice via injection of streptozotocin (STZ). At 3 weeks of STZ, mice were treated with anti-CXCL10 monoclonal antibodies (mAb)/control mAb, and a series of experiments were then conducted at 6 weeks of STZ, including HE staining, western blotting, retinal trypsin digestion, real-time qPCR and enzyme-linked immuno sorbent assay (ELISA). The corresponding kits were used to detect the activity of oxidative stress markers.
RESULTS:
Compared with nondiabetic eyes, DR mice both at 3 and 6 weeks presented the decreases in the total retinal thickness, the retinal outer nuclear layer (ONL) thickness, and the cells of ganglion cell layer (GCL), with the upregulated CXCL10, pro-inflammatory cytokines and malondialdehyde (MDA), as well as the downregulated levels of superoxide dismutase (SOD), glutathione peroxidase (GPx) and CAT, especially in those at 6 weeks, which were attenuated by the anti-CXCL10 mAb treatment. Moreover, in comparison with the DR mice, mice in the DR + anti-CXCL10 mAb group gained the significant decrease in the number of acellular capillaries of retina, with up-regulations of Claudin-5 and ZO-1 and down-regulations of VEGF and FGF-2. The DR mice injected with anti-CXCL10 mAb demonstrated alleviated retinal pathology as compared to mice at 3 weeks of STZ.
CONCLUSION:
Anti-CXCL10 mAb could mitigate the retinal pathology of DR mice, with the decreased inflammation and oxidative stress, thus mediating a delay in the development or disease improvement in patients of DR.
AuthorsZhao-Hui Sun, Fang Li, Yun-Fei Li, Min Wang, Ya-Nan Li, Li Li, Hua Yu, Guang-Xian Tang, Rui-Xue Sun
JournalTissue & cell (Tissue Cell) Vol. 76 Pg. 101745 (Jun 2022) ISSN: 1532-3072 [Electronic] Scotland
PMID35276554 (Publication Type: Journal Article)
CopyrightCopyright © 2022. Published by Elsevier Ltd.
Chemical References
  • Antibodies, Monoclonal
  • Streptozocin
Topics
  • Animals
  • Antibodies, Monoclonal (adverse effects)
  • Diabetes Mellitus, Experimental (drug therapy, pathology)
  • Diabetic Retinopathy (drug therapy, pathology, prevention & control)
  • Disease Models, Animal
  • Humans
  • Mice
  • Retina
  • Streptozocin (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: